de la Torre, R; Farré, M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci., 1 Oct 2004, 25 (10), 505–508. 104 kB. https://doi.org/10.1016/j.tips.2004.08.001
Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. https://doi.org/10.1016/j.forsciint.2011.11.003
Neudõrffer, A; Mueller, M; Martinez, C; Mechan, A; McCann, U; Ricaurte, GA; Largeron, M. Synthesis and neurotoxicity profile of 2,4,5-trihydroxymethamphetamine and its 6-(N-acetylcystein-S-yl) conjugate. Chem. Res. Toxicol., 20 Jun 2011, 24 (6), 968–278. 4.8 MB. https://doi.org/10.1021/tx2001459
Sintas, JA; Vitale, AA. Synthesis of derivatives of [I-131] phenylalkylamines for brain mapping. J. Labelled Compd. Radiopharm., 1 Jan 1998, 41 (1), 53–61. 367 kB. https://doi.org/10.1002/(SICI)1099-1344(199801)41:1<53::AID-JLCR53>3.0.CO;2-K #6 MS,NMR
Dunlap, LE; Andrews, AM; Olson, DE. DARK classics in chemical neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2408–2427. 940 kB. https://doi.org/10.1021/acschemneuro.8b00155 #30